HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study (VISTA)

A Phase 2b Study of the Safety, Pharmacokinetics, and Efficacy of the Combination of TMB-365 and TMB-380 as Maintenance Therapy in HIV-1 Infected Individuals Suppressed With Combination Antiretroviral Therapy

TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry. This study is designed to test the combination of the antibodies as maintenance therapy in HIV infected suppressed individuals discontinuing oral cART for 48 weeks.

Researchers will compare TMB-365/TMB-380 given IV every 8 weeks to continuation of daily oral cART to see if TMB-365/TMB-380 can also maintain viral suppression.

Participants will:

1. Receive TMB-365/TMB-380 infusion or take oral cART as scheduled for 48 weeks
2. Visit the clinic as schedule for checkups and tests

Study Overview

• Status: Active, not recruiting
• Conditions: HIV -1 Infection
• Intervention / Treatment: Drug: TMB-365; Drug: TMB-380; Drug: Baseline ART

• Study Type: Interventional
• Enrollment (Actual): 88
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • San Francisco, California, United States, 94115
      • Quest Clinical Research
  • Florida
    • Fort Lauderdale, Florida, United States, 33316
      • CAN Community Health Fort Lauderdale
    • Ft. Pierce, Florida, United States, 34982
      • Midway Immunology and Research Center (MIRC)
    • Miami Gardens, Florida, United States, 33055
      • CAN Community Health Miami Gardens
    • Oakland Park, Florida, United States, 33334
      • Midland Medical
    • Orlando, Florida, United States, 32803
      • Orlando Immunology Center
    • Sarasota, Florida, United States, 34237
      • CAN Community Health Sarasota
  • Nevada
    • Las Vegas, Nevada, United States, 89104
      • CAN Community Health Las Vegas
  • New York
    • New York, New York, United States, 10065
      • The Rockefeller University
  • Texas
    • Houston, Texas, United States, 77098
      • The Crofoot research Center, INC.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. At least 18 years of age on the day of Screening.
2. Asymptomatic HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by Geenius™ or a second antibody test by a method other than the initial rapid HIV and/or E/CIA test, or by HIV-1 antigen, plasma HIV-1 RNA viral load at or prior to screening.
3. On continuous suppressive cART for at least 6 months prior to Screening with one documented HIV-1 RNA level <50 copies/mL within 6 months of Screening. Continuous cART is defined as no interruptions greater than 3 consecutive days. cART is defined as a DHHS recommended regimen. Study participants should be on a stable oral regimen for at least 3 months prior to Screening.
4. Screening plasma HIV-1 RNA < 50 copies/mL
5. CD4+ T cell count >350 cells/mm3

6. Laboratory values obtained within 35 days prior to the first dose:

   • Hemoglobin ≥ 10.0 g/dL
   • Platelet count ≥ 100,000/mm3
   • Absolute neutrophil count ≥ 1,000/mm3
   • Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x upper limit of normal (ULN)
   • Creatinine clearance (CrCl) of ≥ 50 mL/min
7. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
8. In the opinion of the principal investigator or designee, has understood the information provided; written informed consent needs to be given before any study-related procedures are performed.
9. Persons of childbearing potential sexually active with a partner who can impregnate them, must agree to use one effective method of contraception from the time of signing the consent to completion of the study, and agree to pregnancy testing as per the Schedule of Events and Procedures. Persons of childbearing potential are participants born female who are not surgically sterile (no history of bilateral tubal ligation, hysterectomy, or bilateral salpingo-oophorectomy), are not postmenopausal (at least one year without menses), and are not otherwise sterile by medical evaluation.

Exclusion Criteria:

1. Receipt of any monoclonal antibody for the treatment or prevention of HIV infection.
2. Receiving cabotegravir and rilpivirine intramuscularly as maintenance therapy for HIV-1 infection.
3. Pregnant, planning a pregnancy during the trial period, or lactating.
4. Known allergy/sensitivity or any hypersensitivity to components of the study drug or its formulation, or known allergy to a MAb.
5. History of severe allergic reactions to medications, vaccinations, or monoclonal antibody therapy for other conditions such as COVID.
6. Major psychiatric illness including any history of schizophrenia or severe psychosis, uncontrolled bipolar disorder requiring acute therapy, or suicide attempt in the previous three years.
7. Serious illness requiring systemic treatment and/or hospitalization within 21 days prior to Baseline.
8. Receipt of immunomodulatory agents (e.g., interleukins, interferons, cyclosporine, high dose systemic corticosteroids), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 180 days prior to Baseline.
9. Any chronic or acute medical condition, including chronic Hepatitis B infection, chronic Hepatitis C infection with viremia, drug use and alcohol abuse, which in the opinion of the investigator would interfere with evaluation of the study drug.
10. Lack of adequate venous access.
11. Individuals who have experienced virologic failure during treatment with two or more cART treatment regimens and those being treated with regimens containing either ibalizumab, enfuvirtide, maraviroc, or fostemsavir. Note that a change in treatment regimen for intolerance does not meet criteria for treatment failure.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Combination of TMB-365 and TMB-380 antibodies via IV infusions; Participants will receive an IV infusion of the combination of TMB-365 and TMB-380 each every 8 weeks.	Drug: TMB-365; A monoclonal antibody acts as a HIV post-attachment inhibitor to be given intravenously; Drug: TMB-380; A broadly neutralizing antibody (bNAb) against HIV to be given intravenously; Other Names: VRC07-523LS
Active Comparator: Baseline oral cART; Participants will continue suppressive daily oral cART	Drug: Baseline ART; Baseline ART to be taken daily and orally

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Antiviral activity of TMB-365 and TMB-380 as maintenance therapy compared to daily oral cART	% of subjects with plasma HIV-1 RNA greater than or equal to 50 c/mL at week 48 by snapshot analysis as defined by US FDA	Week 48

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants who experience protocol-defined virologic failure	Virologic failure is defined as two consecutive plasma HIV-1 RNA levels ≥200 copies/mL obtained at least 2 weeks apart.	48 weeks
Pharmacokinetic profile of TMB-365	Mean trough concentrations for TMB-365 in Experimental Arm	Week 48
Pharmacokinetic profile of TMB-380	Mean trough concentrations for TMB-380 in Experimental Arm	Week 48
Safety of maintenance treatment regimen	Number of participants experience grade 3, grade 4, or serious adverse reactions related study treatment.	48 weeks
Immune effects of maintenance therapy	Changes in CD4+ cell counts (cells/mm3) from baseline to Week 48	48 weeks

Collaborators and Investigators

• Sponsor: TaiMed Biologics Inc.

Study record dates

Study Major Dates

• Study Start (Actual): December 16, 2025
• Primary Completion (Estimated): August 1, 2027
• Study Completion (Estimated): August 1, 2027

Study Registration Dates

• First Submitted: October 9, 2025
• First Submitted That Met QC Criteria: October 9, 2025
• First Posted (Actual): October 10, 2025

Study Record Updates

• Last Update Posted (Actual): May 28, 2026
• Last Update Submitted That Met QC Criteria: May 27, 2026
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: Broadly neutralizing antibody (bNAb); HIV-1 maintenance treatment; HIV switch therapy; HIV post-attachment inhibitor; monoclonal antibody (mAb)
• Other Study ID Numbers: TMB-b21

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No